A Semliki Forest virus vector engineered to express IFN alpha induces efficient elimination of established tumors

作者：Quetglas J I; Fioravanti J; Ardaiz N; Medina Echeverz J; Baraibar I; Prieto J; Smerdou C; Berraondo P^*

来源：Gene Therapy, 2012, 19(3): 271-278.

DOI：10.1038/gt.2011.99

• Semliki Forest virus
• interferon alpha
• TC-1 tumor
• antitumor immune response
• E7 antigen of human papillomavirus

Semliki Forest virus (SFV) represents a promising gene therapy vector for tumor treatment, because it produces high levels of recombinant therapeutic proteins while inducing apoptosis in infected cells. In this study, we constructed a SFV vector expressing murine interferon alpha (IFN alpha). IFN alpha displays antitumor activity mainly by enhancing an antitumor immune response, as well as by a direct antiproliferative effect. In spite of the antiviral activity of IFN alpha, SFV-IFN could be produced in BHK cells at high titers. This vector was able to infect TC-1 cells, a tumor cell line expressing E6 and E7 proteins of human papillomavirus, leading to high production of IFNa both in vitro and in vivo. When injected into subcutaneous TC-1 tumors implanted in mice, SFV-IFN was able to induce an E7-specific cytotoxic T lymphocyte response, and to modify tumor infiltrating immune cells, reducing the percentage of T regulatory cells and activating myeloid cells. As a consequence, SFV-IFN was able to eradicate 58% of established tumors treated 21 days after implantation with long-term tumor-free survival and very low toxicity. SFV-IFN was also able to induce significant antitumor responses in a subcutaneous tumor model of murine colon adenocarcimoma. These data suggest that local production of IFNa by intratumoral injection of recombinant SFV-IFN could represent a potent new strategy to treat tumors in patients. Gene Therapy (2012) 19, 271-278; doi:10.1038/gt.2011.99; published online 7 July 2011

• 出版日期2012-3